EGAGenomicsEpigeneticshttps://ega-archive.org/studies/EGAS00001006432EGAEGA study EGAS00001006432Methylation_CONTROLSMethylation_CASESrestrictedEGADiffuse malignant Mesothelioma, Malignant Mesotheliomas, Pleural Mesotheliomas, Mesotheliomas, Occidental, Mesothelioma, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Prospective., Prospective, Malignant Pleural, asbestos-related malignant mesothelioma, white, Pleural Mesothelioma, Malignant, malignant mesothelial neoplasm, Study, malignant tumor of Mesothelium, Caucasian, Malignant Pleural Mesotheliomas, Whites, European, Prospective Study, Studies, advanced malignant mesothelioma, White, diffuse malignant mesothelioma, Caucasoid, CaucasiansFBgn0003149, Biological Markers, Viral Marker, Mesotheliomas, Surrogate Endpoints, PhrB photolyase activity, Clinical Markers, Laboratory, Clinical Marker, Neoplasms, Benign Neoplasm, Biochemical, Endpoint, asbesto, DNA Methylations, Tumor, Serum, photoreactivating enzyme activity, pigmented epithelium, Malignant, Cancer Screening, Surrogate End Points, Surrogate Markers, Laboratory Markers, Para, Caucasian, mPM, sensitive, Biological, Screening, 3, stratum pigmentosa retinae, NUP96, CG5939, epithelium, sensitivity, Biomarker, study, Pleural Mesotheliomas, MOS3, DNA methylation maintenance, deoxyribocyclobutadipyrimidine pyrimidine-lyase activity, Occidental, Clinical, Malignancy, PRECOCIOUS, Biological Marker, pigmented retina, F23A5.3, DNA methylation, Asbest, DNA cyclobutane dipyrimidine photolyase activity, SUPPRESSOR OF AUXIN RESISTANCE 3, Neoplasias, allergic reaction, Immunologic Markers, Immune, Cancer Screening Tests, Markers, malignant neoplasm, Viral Markers, Malignancies, Immunologic Marker, Methylations, F23A5_3, Biologic, Cancer, Tumors, PRE, Viral, Malignant Neoplasm, Mesothelioma, Malignant Mesothelioma, Surrogate Endpoint, whole blood, DmelCG5939, deoxyribonucleic cyclobutane dipyrimidine photolyase activity, Serum Markers, free., End Point, Malignant Pleural, white, Test, Biochemical Markers, pleura mesothelioma, Biologic Marker, Immune Marker, Cancer Screening Test, Programs, Cancer Early Detection, MODIFIER OF SNC1, MT, Benign, Malignant Pleural Mesotheliomas, retinal pigment, prm, Marker, Surrogate End Point, European, deoxyribonucleic photolyase activity, Neoplasm, dipyrimidine photolyase (photosensitive), l(3)S010605, rare (European definition), retinal pigment layer, Caucasoid, Biologic Markers, Caucasians, Malignant Mesotheliomas, primary cancer, Serum Marker, RPE, Screening Tests, End Points, Malignant Pleural Mesothelioma, 0106/05, photolyase activity, Surrogate, Tests, PM/mPM, follow up, Endpoints, Benign Neoplasms, Pleural Mesothelioma, Cancers, Immunologic, Laboratory Marker, malignant tumor, Surrogate Marker, Malignant Neoplasms, p. pigmentosa retinae, phr A photolyase activity, DNA-photoreactivating enzyme, l(3)10631, Biochemical Marker, Whites, Cancer Early Diagnosis, White, deoxyribonucleate pyrimidine dimer lyase (photosensitive), Early Diagnosis of Cancer, DNA, Neoplasia, Methylation, pm, PM, Screening Test, Immune MarkersfalseMalignant mesothelioma EWAS on European prospective studyMalignant pleural mesothelioma (MPM) is a rare and aggressive cancer mainly caused by asbestos exposure. Specific and sensitive non-invasive biomarkers may facilitate and enhance screening programs for the early detection of cancer. We investigated DNA methylation (DNAm) profiles in MPM pre-diagnostic blood samples in a case–control study nested in the European Prospective Investigation into Cancer and nutrition (EPIC) cohort, aiming to characterise DNAm biomarkers associated with MPM. From the EPIC cohort, we included samples from 134 participants who developed MPM during 20 years of follow up and from 134 matched, cancer-free, controls.2022-10-17 08:23:42EGAS000010064329606EGAD00010002367EGAD00010002368EGAC00001002880